Extended thromboprophylaxis with aspirin noninferior to dalteparin for THA patients .
This report has been verified
by one or more authors of the
original publication.
This study has been identified as potentially high impact.
OE's AI-driven High Impact metric estimates the influence a paper is likely to have by integrating signals from both the journal in which it is published and the scientific content of the article itself.
Developed using state-of-the-art natural language processing, the OE High Impact model more accurately predicts a study's future citation performance than journal impact factor alone.
This enables earlier recognition of clinically meaningful research and helps readers focus on articles most likely to shape future practice.
Aspirin versus low-molecular-weight heparin for extended venous thromboembolism prophylaxis after total hip arthroplasty: a randomized trial
Ann Intern Med. 2013 Jun 4;158(11):800-6. doi: 10.7326/0003-4819-158-11-201306040-00004786 total hip arthroplasty (THA) patients were administered daily subcutaneous injections containing low-molecular-weight heparin (dalteparin) for 10 days, starting the next morning after surgery. Afterwards, patients were randomized to receive dalteparin injections in combination with placebo aspirin tablets or receive aspirin tablets combined with placebo dalteparin injections for 28 days, to compare the safety and efficacy of extended thromboprophylaxis. At 90 day follow-up, extended thromboprophylaxis with aspirin was noninferior to dalteparin in terms of venous thromboembolism and bleeding incidences. It should be noted that the study was terminated prematurely as the target sample size was not achieved due to difficulties with patient recruitment.
Unlock the Full ACE Report
You have access to 4 more FREE articles this month.
Click below to unlock and view this ACE Reports
Unlock Now
Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidencecontent for as little as $1.99 per week.
Already have an account? Log in
0 of 4 monthly FREE articles unlocked
